Overview

Response-based Treatment of High-risk Neuroblastoma

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to improve outcome of high risk neuroblastoma by tailoring the treatment intensity of tandem high dose chemotherapy according to the treatment response to induction chemotherapy.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Carboplatin
Cisplatin
Cyclophosphamide
Doxorubicin
Etoposide
Etoposide phosphate
Ifosfamide
Interleukin-2
Isophosphamide mustard
Isotretinoin
Liposomal doxorubicin
Criteria
Inclusion Criteria:

- Patients with newly diagnosed high risk neuroblastoma

- Patients with informed consent

Exclusion Criteria:

- Patients with progressive disease or relapse

- Patients who underwent high dose chemotherapy before

- Patients with organ dysfunction as follows (creatinine elevation > 3 x upper limit of
normal, Total bilirubin > 3 x upper limit of normal, aspartate transaminase/alanine
transaminase > 5 x upper limit of normal), ejection fraction <40%

- Pregnant or nursing women